Published in Bioorg Med Chem Lett on February 03, 2011
From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules. ChemMedChem (2013) 0.87
Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. J Med Chem (2013) 0.85
Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models. J Biol Chem (2013) 0.83
Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening. Bioorg Med Chem (2014) 0.75
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem (1997) 6.99
Mammalian cyclin-dependent kinases. Trends Biochem Sci (2005) 5.54
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature (1999) 5.53
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature (2010) 5.01
GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol (2003) 4.60
p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature (1994) 3.95
Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. J Am Chem Soc (2008) 2.81
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem (2001) 2.79
A brain-specific activator of cyclin-dependent kinase 5. Nature (1994) 2.71
Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 2.17
Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds. Bioorg Med Chem (2004) 2.13
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem (2000) 1.93
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther (2010) 1.93
Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem (2000) 1.89
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 1.87
Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci (2002) 1.82
Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A (2000) 1.73
Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol (2000) 1.71
Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron (2001) 1.68
Structure and regulation of the CDK5-p25(nck5a) complex. Mol Cell (2001) 1.57
Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem Biol (1999) 1.26
Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim Biophys Acta (2006) 1.20
Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem (2004) 1.14
Mechanism of CDK5/p25 binding by CDK inhibitors. J Med Chem (2005) 1.11
Identification of the 23 kDa subunit of tau protein kinase II as a putative activator of cdk5 in bovine brain. FEBS Lett (1994) 1.07
Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J Neurosci (2008) 1.05
No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro. Proc Natl Acad Sci U S A (2010) 1.05
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorg Med Chem Lett (2004) 1.03
The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect (2006) 1.00
Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Chem Biol (2005) 0.98
Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease. Curr Alzheimer Res (2004) 0.97
Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem (2003) 0.94
Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis. J Biol Chem (2004) 0.89
Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions. Curr Pharm Des (2009) 0.87
Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors. Bioorg Med Chem (2002) 0.83
Development of an assay to screen for inhibitors of tau phosphorylation by cdk5. J Biomol Screen (2004) 0.83
Clubbed thiazoles by MAOS: a novel approach to cyclin-dependent kinase 5/p25 inhibitors as a potential treatment for Alzheimer's disease. Bioorg Med Chem (2007) 0.82
Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins. Bioorg Med Chem (2009) 0.82
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem (2010) 0.81
Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives. Bioorg Med Chem (2003) 0.80
Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors. Bioorg Med Chem (2007) 0.80
A catch-and-release strategy for the combinatorial synthesis of 4-acylamino-1,3-thiazoles as potential CDK5 inhibitors. Bioorg Med Chem Lett (2003) 0.78
Synthesis and cytotoxic activity of new azepino[3',4':4,5]pyrrolo[2,1-a]isoquinolin-12-ones. Bioorg Med Chem (2009) 0.77
Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors. Bioorg Med Chem Lett (2007) 0.77
Clausine Z, a new carbazole alkaloid from Clausena excavata with inhibitory activity on CDK5. Pharmazie (2005) 0.76
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res (2005) 18.58
Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol (2005) 11.63
A microRNA array reveals extensive regulation of microRNAs during brain development. RNA (2003) 9.76
Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol (2008) 9.24
MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell (2009) 8.14
Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. Proc Natl Acad Sci U S A (2003) 7.95
Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells (2005) 6.72
The Amphimedon queenslandica genome and the evolution of animal complexity. Nature (2010) 5.11
MicroRNA profiling of the murine hematopoietic system. Genome Biol (2005) 4.94
BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med (2008) 4.20
MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res (2008) 3.70
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet (2007) 2.98
Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet (2010) 2.95
HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Mol Cell (2010) 2.91
Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis (2011) 2.78
Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol (2003) 2.72
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol (2012) 2.65
Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics (2008) 2.50
MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett (2008) 2.48
Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nat Med (2007) 2.48
CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem (2003) 2.27
MicroRNAs potentiate neural development. Neuron (2009) 2.25
Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst (2004) 2.22
PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. Genes Dev (2008) 2.15
Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell (2010) 2.08
Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab (2008) 2.06
Somatodendritic microRNAs identified by laser capture and multiplex RT-PCR. RNA (2007) 2.01
Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A (2004) 2.00
A prospective randomized equivalence trial of the GlideScope Cobalt® video laryngoscope to traditional direct laryngoscopy in neonates and infants. Anesthesiology (2012) 2.00
A post-synaptic scaffold at the origin of the animal kingdom. PLoS One (2007) 1.96
A coordinated local translational control point at the synapse involving relief from silencing and MOV10 degradation. Neuron (2009) 1.96
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A (2009) 1.94
Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model. J Neurosci Res (2010) 1.89
Influence of patient and hospital characteristics on anesthesia time in medicare patients undergoing general and orthopedic surgery. Anesthesiology (2007) 1.87
Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol (2003) 1.85
Distribution of 5-hydroxymethylcytosine in different human tissues. J Nucleic Acids (2011) 1.82
Deletion of the neuron-specific protein delta-catenin leads to severe cognitive and synaptic dysfunction. Curr Biol (2004) 1.80
Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. J Am Chem Soc (2015) 1.76
Synaptic tagging -- who's it? Nat Rev Neurosci (2002) 1.75
Parkin ubiquitinates Drp1 for proteasome-dependent degradation: implication of dysregulated mitochondrial dynamics in Parkinson disease. J Biol Chem (2011) 1.75
MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J (2009) 1.74
Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett (2005) 1.72
Biomedical applications of graphene. Theranostics (2012) 1.67
3D aperiodic hierarchical porous graphitic carbon material for high-rate electrochemical capacitive energy storage. Angew Chem Int Ed Engl (2008) 1.64
MicroRNA regulation of neural stem cells and neurogenesis. J Neurosci (2010) 1.64
Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood (2011) 1.61
The high prevalence of hypovitaminosis D in China: a multicenter vitamin D status survey. Medicine (Baltimore) (2015) 1.60
The Erbin PDZ domain binds with high affinity and specificity to the carboxyl termini of delta-catenin and ARVCF. J Biol Chem (2002) 1.59
Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci U S A (2011) 1.56
The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res (2005) 1.56
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol Aging (2013) 1.53
Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res (2010) 1.51
The mechanism of RNA 5′ capping with NAD+, NADH and desphospho-CoA. Nature (2016) 1.50
Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer (2010) 1.50
MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell (2010) 1.49
MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life (2009) 1.46
Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsiveness. Ann Thorac Surg (2011) 1.46
Retrograde intrarenal surgery for the treatment of renal stones: is fluoroscopy-free technique achievable? Urolithiasis (2015) 1.44
Long-term renal changes in the liver-specific glucokinase knockout mouse: implications for renal disease in maturity-onset diabetes of the young 2. Transl Res (2010) 1.44
Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res (2006) 1.44
Whole-genome sequencing of giant pandas provides insights into demographic history and local adaptation. Nat Genet (2012) 1.43
High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. J Pediatr (2009) 1.43
Consumption of a high-fat diet alters the homeostatic regulation of energy balance. Physiol Behav (2004) 1.43
RNAi functions in cultured mammalian neurons. Proc Natl Acad Sci U S A (2002) 1.42
Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem (2004) 1.42
Estimating anesthesia and surgical procedure times from medicare anesthesia claims. Anesthesiology (2007) 1.41
High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma. J Urol (2012) 1.40
Detection of a microRNA signal in an in vivo expression set of mRNAs. PLoS One (2007) 1.40
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell (2011) 1.40
Electronic health record-based decision support to improve asthma care: a cluster-randomized trial. Pediatrics (2010) 1.40
miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem (2012) 1.39
The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem (2008) 1.39
Identification of piRNAs in the central nervous system. RNA (2011) 1.39
The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule. J Neurosci (2009) 1.38
Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg Med Chem Lett (2005) 1.38
miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res (2014) 1.38
Comparison of four spatial interpolation methods for estimating soil moisture in a complex terrain catchment. PLoS One (2013) 1.37
MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Lett (2011) 1.37
MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Lett (2012) 1.36
A new class of small molecule inhibitor of BMP signaling. PLoS One (2013) 1.36
Changes in prognosis after the first postoperative complication. Med Care (2005) 1.35
Hypovirus papain-like protease p29 suppresses RNA silencing in the natural fungal host and in a heterologous plant system. Eukaryot Cell (2006) 1.35
The structural basis of Cryptosporidium -specific IMP dehydrogenase inhibitor selectivity. J Am Chem Soc (2010) 1.35
Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One (2010) 1.35
Dual regulation of neuronal morphogenesis by a delta-catenin-cortactin complex and Rho. J Cell Biol (2003) 1.35
Highly conserved O-fucose sites have distinct effects on Notch1 function. J Biol Chem (2005) 1.35
Triazole inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem (2009) 1.33
MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells. J Interferon Cytokine Res (2006) 1.32
Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res (2008) 1.31
High throughput sequencing technology reveals that the taxoid elicitor methyl jasmonate regulates microRNA expression in Chinese yew (Taxus chinensis). Gene (2009) 1.30
Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. J Biol Chem (2004) 1.30
MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. J Biol Chem (2012) 1.30
De novo sequencing and a comprehensive analysis of purple sweet potato (Impomoea batatas L.) transcriptome. Planta (2012) 1.29
MicroRNAs: regulators of oncogenesis and stemness. BMC Med (2008) 1.29
Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis (2006) 1.28
EB1 promotes Aurora-B kinase activity through blocking its inactivation by protein phosphatase 2A. Proc Natl Acad Sci U S A (2008) 1.28
Genotypic variants at 2q33 and risk of esophageal squamous cell carcinoma in China: a meta-analysis of genome-wide association studies. Hum Mol Genet (2012) 1.28
Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis (2010) 1.28